Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

389
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
389
Urea Cycle01:23

Urea Cycle

47.5K
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
47.5K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

421
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
421
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

626
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
626
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

317
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
317
Physical Properties of Amines01:26

Physical Properties of Amines

3.6K
Amines with low molecular weight are usually gaseous at room temperature, while those with high molecular weight are liquid or solids in nature. Usually, low molecular weight amines have a rotten fish-like smell. Diamines typically have a pungent smell. For instance, cadaverine and putrescine, depicted in Figure 1, are two molecules responsible for decaying tissue.
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spontaneous bacterial peritonitis (SBP) in ascites due to advanced pancreatic adenocarcinoma in the absence of chronic liver disease.

Revista espanola de enfermedades digestivas·2025
Same author

Lymphocytic esophagitis - A little-known cause of dysphagia.

Revista espanola de enfermedades digestivas·2024
Same author

Primary follicular lymphoma of the duodenum as an incidental finding on upper gastrointestinal endoscopy.

Revista espanola de enfermedades digestivas·2024
Same author

Association of microscopic colitis and enteropathy due to olmesartan.

Revista espanola de enfermedades digestivas·2024
Same author

Endoscopic endoluminal therapy with the Eso-SPONGE® system for the treatment of spontaneous esophageal perforation with associated paraoesophageal collection.

Revista espanola de enfermedades digestivas·2023
Same author

Upper gastrointestinal bleeding secondary to late gastric metastasis of renal cell carcinoma.

Revista espanola de enfermedades digestivas·2022

Related Experiment Video

Updated: Nov 1, 2025

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

11.7K

Capecitabine-induced hyperammonemic encephalopathy.

Carolina Cerrella Cano1, Eduardo Junquera Alonso2, Marina Terroba Alonso3

  • 1Aparato Digestivo, Hospital Universitario San Agustín, España.

Revista Espanola De Enfermedades Digestivas
|June 22, 2021
PubMed
Summary

A 79-year-old man developed hyperammonemic encephalopathy after starting capecitabine for pancreatic cancer. Symptoms resolved rapidly after discontinuing the chemotherapy drug.

More Related Videos

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.6K
Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

11.5K

Related Experiment Videos

Last Updated: Nov 1, 2025

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

11.7K
Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.6K
Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

11.5K

Area of Science:

  • Oncology
  • Neuroscience
  • Pharmacology

Background:

  • A 79-year-old male with a history of resected stage-III pancreatic adenocarcinoma presented with local progression.
  • The patient was initiated on capecitabine monotherapy for treatment of radiographic disease progression.

Observation:

  • Within 48-72 hours of starting capecitabine, the patient developed disorientation, asterixis, and nausea.
  • Laboratory tests revealed elevated serum ammonia levels (221 μmol/L) with preserved liver function.
  • Abdominal and brain CT scans excluded other causes of encephalopathy or tumor progression.

Findings:

  • The patient's clinical presentation and laboratory abnormalities were attributed to capecitabine-induced hyperammonemic encephalopathy.
  • Discontinuation of capecitabine, implementation of anti-encephalopathy measures, and intravenous hydration resulted in complete symptom resolution and normalization of serum ammonia levels.

Implications:

  • This case highlights a rare but significant adverse effect of capecitabine, emphasizing the importance of considering drug toxicity in patients presenting with encephalopathy.
  • Prompt recognition and management, including drug cessation and supportive care, are crucial for favorable outcomes in capecitabine-induced hyperammonemic encephalopathy.
  • Further investigation may be warranted to elucidate the precise mechanism of capecitabine-induced hyperammonemia.